

Title: Cardiovascular Disease Risk Factor Responses to a Type 2 Diabetes Care Model Including Nutritional Ketosis at One Year: An Open Label, Non-Randomized, Controlled Study

Nasir H. Bhanpuri, PhD (Corresponding Author)

Virta Health, San Francisco, CA, USA

Sarah J. Hallberg, DO, MS

Indiana University Health Arnett, Medically Supervised Weight Loss, Lafayette, IN, USA

Virta Health, San Francisco, CA, USA

Paul T. Williams, PhD

Independent Consultant, Lafayette, CA, USA

Amy L. McKenzie, PhD

Virta Health, San Francisco, CA, USA

Kevin D. Ballard, PhD

Miami University, Oxford, OH, USA

Wayne W. Campbell, PhD

Purdue University, West Lafayette, IN, USA

James P. McCarter, MD, PhD

26 Virta Health, San Francisco, CA, USA

27 Washington University School of Medicine, Department of Genetics, St. Louis, MO, USA

28 ████████████████████

29 Stephen D. Phinney, MD, PhD

30 Virta Health, San Francisco, CA, USA

31 ████████████████████

32 Jeff S. Volek, PhD, RD

33 Virta Health, San Francisco, CA, USA

34 The Ohio State University, Department of Human Sciences, Columbus, OH, USA

35 ████████████████████

36

Abstract

Background

Cardiovascular disease (CVD) is a leading cause of death among adults with type 2 diabetes mellitus (T2D). We recently reported that glycemic control in patients with T2D can be significantly improved through a continuous care intervention (CCI) including nutritional ketosis. The purpose of this study was to examine CVD risk factors in this cohort.

Methods

We investigated CVD risk factors in patients with T2D who participated in a one year open label, non-randomized, controlled study. The CCI group (n = 262) received treatment from a health coach and medical provider. A usual care (UC) group (n = 87) was independently recruited to track customary T2D progression. Circulating biomarkers of cholesterol metabolism and inflammation, blood pressure (BP), carotid intima media thickness (cIMT), multi-factorial risk scores and medication use were examined.

Results

The CCI group consisted of 262 patients (baseline mean(SD): age 54(8) y, BMI 40.4(8.8) kg/m²). Intention-to-treat analysis (% change) revealed the following at 1-year with P values < 0.0019 indicating statistical significance after adjustment for multiple comparisons: total LDL-particles (LDL-P) (-4.9%, P=0.02), small LDL-P (-20.8%, P=1.2x10⁻¹²), LDL-P size (+1.1%, P=6.0x10⁻¹⁰), ApoB (-1.6%, P=0.37), ApoA1 (+9.8%, P<10⁻¹⁶), ApoB/ApoA1 ratio (-9.5%, P=1.9x10⁻⁷), triglyceride/HDL-C ratio (-29.1%, P<10⁻¹⁶), large VLDL-P (-38.9%, P=4.2x10⁻¹⁵), and LDL-C (+9.9%, P=4.9x10⁻⁵). Additional effects were reductions in blood pressure, high sensitivity C-reactive protein, and white blood cell count (all P<1x10⁻⁷) while cIMT was unchanged. The 10-year atherosclerotic cardiovascular disease (ASCVD) risk score decreased -11.9% (P=4.9x10⁻⁵). Antihypertensive medication use was discontinued in 11.4 % of CCI participants (P=5.3x10⁻⁵). The UC group of 87 patients (baseline mean(SD): age 52(10)y, BMI 36.7(7.2) kg/m²) showed no significant changes. After adjusting for baseline differences when comparing

CCI and UC groups, significant improvements for the CCI group included small LDL-P, ApoA1, triglyceride/HDL-C ratio, HDL-C, hs-CRP, and ASCVD score. The CCI group showed a greater rise in LDL-C.

Conclusions

A continuous care treatment including nutritional ketosis in patients with T2D improved most biomarkers of CVD risk after one year. The increase in LDL-cholesterol appeared limited to the large LDL subfraction. LDL particle size increased, total LDL-P and ApoB were unchanged, and inflammation and blood pressure decreased.

Trial registration

Clinicaltrials.gov: NCT02519309. Registered 10 August 2015

Keywords

ketosis, carbohydrate restriction, type diabetes, cardiovascular disease, risk factor, atherogenic dyslipidemia, inflammation, blood pressure, antihypertensive medication, continuous remote care

Background

Despite advances in the prevention and treatment of cardiovascular disease (CVD), it remains the leading cause of death in adults across the world [1]. Specifically, among those with type 2 diabetes (T2D) in the U.S., CVD accounts for 44% of mortality [2]. T2D rates have doubled over the past twenty years [3] and CVD risk increases two to four-fold with a diagnosis of T2D [4], warranting the identification of novel interventions to combat T2D. Intensive lifestyle interventions with dietary carbohydrate restriction [5-8], including the recently described continuous remote care model, which helps patients with T2D sustain nutritional ketosis [9,10], have demonstrated improved glycemic control concurrent with medication

reduction. However, the long-term sustainability and impact of these interventions on CVD risk and lipid profiles remains a subject of debate [11,12].

Atherogenic dyslipidemia, a known risk factor for CVD [13], is highly prevalent in patients with T2D [14] and tightly linked to high-carbohydrate diets[15]. The condition is characterized by increased triglycerides, decreased high-density lipoprotein cholesterol concentration (HDL-C) and increased small low-density lipoprotein particle number (small LDL-P). Evidence suggests that increased very low-density lipoprotein particle number (VLDL-P), and in particular large VLDL-P, may be one of the key underlying abnormalities in atherogenic dyslipidemia [14,16-18]. Elevated concentrations of small LDL are often associated with increased total LDL particle number (LDL-P) and ApoB [19,20]. Particularly in patients with insulin resistance and T2D, elevated LDL-P and ApoB may exist even with normal to low LDL-C values [19,21,22]. Reliance on LDL-C for risk assessment in T2D patients may miss the impact of atherogenic dyslipidemia and elevated LDL-P. It has been proposed that LDL-P or ApoB may be superior to LDL-C as a predictor of CVD [22-25].

Previous studies of carbohydrate restriction of up to 1-year found a consistent decrease in triglycerides and increase in HDL-C, while LDL-C slightly increased or decreased [15,26-28]. Although LDL-C is a risk factor for CVD, low LDL-C may belie elevations in small LDL, LDL-P or ApoB. Conversely, increased LDL-C with a low carbohydrate diet may primarily reflect the large LDL subfraction and may not increase CVD risk if total LDL-P or ApoB concentrations are unchanged or decline.

Inflammation, as assessed by elevated high-sensitivity C-reactive protein (hsCRP) or white blood cell count (WBC) [29-32], is an independent CVD risk factor and is involved in all stages of atherogenesis [33]. Inflammation is often observed in T2D concurrent with atherogenic dyslipidemia [34] and represents an additional CVD risk even in individuals with low to normal LDL-C [35,36]. Hypertension is an additive risk factor in this patient population. Tighter blood pressure control has been associated with

reduction in the risk of deaths related to diabetes. This included decreased CVD, stroke and microvascular complications [37].

For this open label, non-randomized, controlled, before-and-after study, we investigated the effects of a continuous care intervention (CCI) on CVD risk factors. The CCI included individualized digital support with telemedicine, health coaching, education in nutritional ketosis, biometric feedback, and an online peer-support community. Given the multi-faceted pathophysiology of CVD, we assessed the one-year responses in several biomarkers related to cholesterol and lipoprotein metabolism, blood pressure, and inflammation, as well as carotid intima media thickness (cIMT) and medication use. Some results were previously reported in relation to glycemic control [10] and are presented here as they pertain to CVD risk.

Methods

Intervention

As previously described [9,10], we utilized a prospective, longitudinal study design with a cohort of patients with T2D from the greater Lafayette, Indiana, USA, region who self-selected to participate in the CCI (Clinicaltrials.gov Identifier NCT02519309). Patients in the CCI were provided access to a web-based software application (app) for biomarker reporting and monitoring including body weight, blood glucose and blood betahydroxybutyrate (BHB; a marker of ketosis). The remote care team consisted of a health coach and physician or nurse practitioner who provided nutritional advice and medication management, respectively. Patients were guided by individualized nutrition recommendations to achieve and sustain nutritional ketosis. CCI participants self-selected to receive education via either an onsite

group setting (CCI-onsite) or via the app (CCI-web). Social support was provided via an online peer community. This study was approved by the Franciscan Health Lafayette Institutional Review Board, and participants provided written informed consent.

Glycemic control medication management was previously described [9,10]. For participants with a history of hypertension, a home automatic sphygmomanometer was supplied. Participants reported their home readings in the app daily to weekly depending on recent control and instruction from the supervising physician. Antihypertensive prescriptions were adjusted based on home readings and reported symptoms. Health coaches responded to patient app reported readings of systolic blood pressure less than 110 mmHg with specific questions about symptoms of hypotension. Following resolution of hypertension, diuretics were the first antihypertensive medications to be discontinued, followed by beta blockers, unless the participant had a history of coronary artery disease. Angiotensin-converting-enzyme inhibitors (ACEs) and angiotensin II receptor blockers (ARBs) were generally continued due to known renal protection with diabetes [38,39]. Statin medications were adjusted when appropriate to maintain a goal of LDL-P under 1000 nmol·L⁻¹ or participant preference after full risk-benefit discussion.

To track T2D progression in the same geography and health system as the CCI, an independent cohort of patients with T2D who received usual care (UC) were recruited. These patients were referred to registered dietitians providing dietary advice according to American Diabetes Association guidelines [40].

Outcome Measures

Anthropometrics and vital signs for the CCI group were obtained at baseline, 70 days, and one year. A stadiometer was used to assess height and used in the calculation of body mass index. A calibrated scale in the clinic measured weight to the nearest 0.1 lb (Model 750, Detecto; Webb City, MO, USA) and values were converted to kg. Participants were provided a cellular-connected home scale for daily weight. Blood pressure was obtained manually by trained staff after participants rested in a seated position for

five minutes. Adverse events were reported and reviewed by the Principal Investigator and the Institutional Review Board.

Fasting blood draws for the CCI group were collected at baseline, 70 days, and one-year follow-up (ranging from 11 - 15 months). Blood analytes were determined via standard procedures at a Clinical Laboratory Improvement Amendment (CLIA) accredited laboratory on the day of sample collection or from stored serum. Serum aliquots were stored at -80°C and thawed for determination of ApoB, ApoA1, total cholesterol, triglycerides, and direct HDL-C concentrations by FDA approved methods (Cobas c501, Roche Diagnostics; Indianapolis, IN, USA). LDL was calculated using the Friedewald equation [41]. Lipid subfractions were quantified using clinical NMR LipoProfile® (LabCorp, Burlington NC, USA; [42]). The LipoProfile3 algorithm used in the present investigation was used previously to relate lipid subfractions to CVD risk [35,43,44]. The NMR-derived lipoprotein insulin resistance score (LP-IR) is proposed to be associated with the homeostasis model assessment of insulin resistance (HOMA-IR) and glucose disposal rate (GDR) [45]. The multifactorial 10-year atherosclerotic cardiovascular disease (ASCVD) risk score was also computed [46].

Anthropometrics, vital signs and fasting blood draws for the UC group were obtained at baseline and one year as described above using the same clinical facilities and laboratory and data collection methods. Home biometrics for the UC group were not tracked and 70-day outcomes were not measured.

Carotid ultrasonography for cIMT measure was performed at baseline and one year in CCI and UC groups to characterize atherosclerotic risk. Ultrasound technicians were trained according to protocols that were previously tested and used to assess subclinical atherosclerosis [47,48]. The right and left common carotid arteries were imaged one cm distal to the carotid bulb using a L12-3 multi-frequency linear-array transducer attached to a high-resolution ultrasound system (Phillips EPIQ 5, Amsterdam, Netherlands). Longitudinal images were captured in three imaging planes: anterior, lateral, and posterior.

Digital images were analyzed using edge-detection software (Carotid Analyzer for Research; Medical Imaging Application, Coralville, IA) to trace the lumen-intima and intima-medial boundaries of the artery. Analyses were performed by the same blinded investigator to obtain right and left mean arterial diameter and mean cIMT.

Statistics

JMP software (version 5.1, SAS Institute; Cary, SC, USA) was used for all statistical analyses except multiple imputation. Multiple imputation, conducted with Stata software (version 11, StataCorp; College Station, TX, USA), was used to estimate means and standard errors describing the variability between imputations. Seven hundred imputations from multivariate normal regression were run to estimate the missing values (4% missing at baseline and 22% missing at one year). Two-sample t-tests were used to test for significance of the differences in baseline biomarker values between groups. Two-sample t-tests were also used to test for differences between one-year changes between groups. Paired t-tests and analysis of covariance (ANCOVA) when adjusted for baseline covariates (sex, age, baseline BMI, and African-American race) were used to test for significance of within-group changes. To reduce skewness before testing for significance, triglyceride, triglyceride/HDL-C ratio and hsCRP were first log-transformed, however aside from P values, the tables present results from the untransformed data. Percent change in a given biomarker was calculated as the mean difference value divided by the mean baseline value. The standard error of percent change of a given biomarker was calculated as the standard error of the change divided by the mean baseline value. Significant changes in proportions (e.g. medication use) were tested using McNemar’s test with continuity correction in completers, and linear regression of the changes in the dichotomous states when missing outcome data were imputed.

Throughout the manuscript, standard deviations are presented within parentheses and standard errors are presented following “ \pm ” symbol. Nominal significance levels (P) are presented in the tables; however, a

significance level of $P < 0.0019$ ensures simultaneous significance at $P < 0.05$ for a Bonferroni adjustment for the 26 variables examined. Unless otherwise noted, results presented are intention-to-treat analyses (all starters) with missing values estimated by imputation. Some results are designated as completer analyses (excluding participants who withdrew or lacked biomarkers at one year).

Results

Baseline characteristics of participants

The baseline characteristics of the 262 T2D participants who began the CCI are shown in Table 1. There were no significant differences in baseline characteristics between groups self-selecting web-based (CCI-web) and onsite education (CCI-onsite) (Supplementary Table 1) nor were there significant differences in biomarker changes at one year between the groups (Supplementary Table 2). Therefore, results for the two groups were combined for further analyses.

The baseline characteristics of participants with measurements at both baseline and one year were not significantly different from dropouts and participants with missing data after correcting for multiple comparisons (Supplementary Table 1).

An independently recruited UC group of 87 T2D participants, which provided an observational comparison group from the same geography and health system, showed no significant differences from the CCI group in baseline characteristics except mean body weight and BMI were higher in the CCI versus the UC group (Table 1, $P < 0.001$).

Changes in biomarkers of CVD risk at one year

237
238 Two-hundred eighteen (83%) participants remained enrolled in the CCI group at one year. One-year
239 changes in CVD biomarkers are detailed in Table 2 and percent changes from baseline are shown in
240 Figure 1. The within-CCI group changes in the following lipids and lipoproteins were all statistically
241 significant after adjusting for multiple comparisons ($P < 0.0019$), reported here as mean percent difference
242 from baseline: ApoA1 (+9.9%), ApoB/ApoA1 ratio (-9.5%), triglycerides (-24.4%), LDL-C (+9.6%),
243 HDL-C (+18.1%), triglyceride/HDL-C ratio (-29.1%), large VLDL-P (-38.9%), small LDL-P (-20.8%),
244 LDL-particle size (+1.1%), total HDL-P (+4.9%), and large HDL-P (+23.5%). There were no significant
245 changes after adjusting for multiple comparisons in total LDL-P (-4.9%, $p = 0.02$) or ApoB (-1.6%,
246 $p = 0.37$).

247
248 The CCI group experienced significant reductions in systolic BP (-4.8%), diastolic BP (-4.3%), hs-CRP (-
249 39.3%) and WBC count (-9.1%). Significant reductions were observed in overall use of antihypertensive
250 medication (-11.4%) and diuretics (-9.6%) whereas changes in ACE or ARB (0.7%) and statin (-3.3%)
251 use were not significant. Significant reductions were observed in both multivariate metrics: 10-year
252 ASCVD risk (-11.9%) and LP-IR (-19.6%). There was no significant change in cIMT (averaged right and
253 left values). In addition, changes in cIMT were not significantly correlated with baseline LDL-P or LDL-
254 C, or changes in LDL-P or LDL-C (all $p \geq 0.33$).

255
256 One-year results from the UC group are provided in Table 2 and Figure 1. Within the UC group, after
257 adjustment for multiple comparisons there were no significant changes at one year. After adjusting for
258 differences in baseline characteristics and multiple comparisons, the changes observed at one year for the
259 following biomarkers were significantly different between the CCI and UC groups (mean Δ CCI – mean
260 Δ UC, where Δ is one year minus baseline): small LDL-P (-178 nmol·L⁻¹), ApoA1 (+16 mg·dL⁻¹),
261 triglyceride/HDL-C ratio (-3.1), LDL particle size (+0.31 nm), HDL-C (+8 mg·dL⁻¹), LDL-C (+22 mg·dL⁻¹)
262 ¹), hs-CRP (-4.0 mg·dL⁻¹), and LP-IR (-12).

Range of outcomes

The distribution and range of intervention response for the CCI and UC groups were compared for LDL-P, small LDL-P, large VLDL-P, ApoB, ApoA1, ApoB/ApoA1 ratio, and TG/HDL-C ratio (Supplementary Figure 1). Ranges of change observed in the CCI group were within the ranges observed in the UC group for increases in LDL-P, small LDL-P, ApoB and ApoB/ApoA1 ratio. There were two CCI participants (2/203, 1.0%) whose change in large VLDL-P exceeded the maximum observed in the UC group (15.2 nmol·L⁻¹). There was one CCI participant (1/185, 0.5%) whose change in ApoA1 was less than the minimum observed in the UC group (58 mg·dL⁻¹) and one CCI participant (1/186, 0.5%) whose change in triglyceride/HDL-C ratio was higher than the maximum observed in the UC group (64.9).

Discussion

This study demonstrates that a CCI utilizing remote physician and health coach support with nutritional ketosis beneficially altered most CVD risk factors in patients with T2D at one year. Changes included: decreased small LDL-P, triglycerides, blood pressure and antihypertensive medication, hsCRP, and WBC count; increased HDL-C and LDL particle size; no change in LDL-P, ApoB, and cIMT and an increase in LDL-C. Combined with the previously reported improvements in glycemic control and reduction in obesity [10], which reduce CVD risk [49], these results demonstrate multiple additional benefits of the CCI with the exception of increased LDL-C.

Studies of dietary carbohydrate restriction, with a presumed increase in saturated fat intake, have shown modest changes in LDL-C levels [15,26-28,50]. The mean 10 mg/dL change observed in the CCI group in

this study is numerically higher than the upper range of values reported by meta-analysis of lipid changes over one year related to carbohydrate restriction (-7 mg/dl to +7 mg/dl) [51]. Higher LDL-C is related to increased CVD risk [52,53], but also is *inversely* correlated with mortality in two large prospective studies and a systemic review [54-56]. Additionally, there is no evidence that increasing or decreasing LDL-C with diet interventions has any impact on mortality. LDL-C increased in the current study but both ApoB and LDL-P, measures found to be better predictors of CVD risk, did not change significantly [20-23,25,57]. In addition, the reduction in small LDL-P, increase in LDL size, and decrease in large VLDL-P that occurred in the present investigation are also associated with reduced CVD risk [58-60].

While mean response of CCI participants demonstrated an improvement in most lipid biomarkers and CVD risk factors other than LDL-C, we investigated whether a minority of participants might have unfavorable responses to the intervention. Our results suggest that a small number of participants ($\leq 1\%$) demonstrated changes at one year outside the range of what was observed in a usual care population (Supplementary Figure 1). Thus, these results counter the concern that a significant portion of participants may have an extremely adverse reaction to the CCI (due to presumed increase in saturated fat intake) as compared to UC.

Inflammation is directly involved in all aspects of the pathogenesis of CVD [33]. High-sensitivity CRP and WBC count are widely accepted markers of inflammation and risk factors for CVD [29-32]. In addition to reducing cholesterol, reduction in inflammation may be a secondary mechanism of statins in lowering CVD risk [61-63]. The present study demonstrated a 39% reduction of hsCRP and 9% reduction in WBC count in the CCI, indicating a significant reduction in inflammation at one year. This response may be due in part to suppression of the NLRP3 inflammasome by BHB [64].

The reduction of blood pressure with concurrent reduction in antihypertensive medication was also significant. Blood pressure goals were recently reduced [65] and strong evidence exists that elevated

blood pressure is a primary cardiovascular risk factor [66]. An analysis of a large T2D population suggested that antihypertensive medication may have limited effectiveness in reducing the prevalence of hypertension in these patients [67], whereas a study of weight loss interventions showed that a decrease in blood pressure predicted regression of carotid vessel wall volume [68]. Thus, additional lifestyle interventions that can augment blood pressure reduction such as the CCI described here may reduce CVD events. Additionally, the antihypertensives that were primarily decreased in the current study were shown to increase the risk for diabetes [69]. Their removal may represent further metabolic benefit.

Carotid intima media thickness (cIMT) is a non-invasive measure of subclinical atherosclerosis that is significantly associated with CVD morbidity and mortality [47,48,70,71]. However, a recent meta-analysis in 3,902 patients with T2D found that cIMT progression over an average of 3.6 years did not correlate with CVD events [70]. We found no significant change in cIMT from baseline to one year in either the CCI or UC groups. Progression or regression of cIMT may take multiple years to manifest and may require a larger cohort to achieve statistical significance [71]. In summary, the cIMT results from this study provide no evidence of vascular harm or benefit from one year of nutritional ketosis in patients with T2D.

Strengths and limitations of the study

Prior studies have demonstrated favorable improvements in atherogenic dyslipidemia with minimal or no change in LDL-C and LDL-P following managed ketogenic diets in small short-term randomized trials. This study's strengths include its larger cohort with high retention, prospective design and one-year duration. The study was the first to assess ApoB and ApoA1 in a T2D population adhering to a ketogenic diet. This study also has real-world application due to the outpatient setting without the use of meal replacements or food provisions.

Limitations of this study include the lack of randomization between the CCI and UC groups. In addition, the intervention provided to CCI participants was of greater intensity than UC. This was a single site study and the racial composition of study participants was predominantly Caucasian. The study was not of sufficient size and duration to determine significant differences in CVD morbidity or mortality. Since the intervention led to concurrent weight loss and improvements in cardiovascular health, it is difficult to conclude how much of the improvement can be attributed to weight loss versus other simultaneous metabolic changes. Future trials could include a longer multi-site, randomized controlled trial to allow for hard end point evaluation. Greater racial and ethnic diversity, a broader age range, and greater disease severity could also be evaluated.

Conclusions

A T2D intervention combining technology-enabled continuous remote care with individualized plans encouraging nutritional ketosis has demonstrated diabetes status improvement while improving many CVD risk factors including atherogenic dyslipidemia, inflammation and blood pressure while decreasing use of antihypertensive medications. Ongoing research will determine the continued safety, sustainability, and effectiveness of the intervention.

List of abbreviations

ACE: angiotensin-converting-enzyme inhibitors
ApoA1: apolipoprotein A1
ApoB: apolipoprotein B
ARB: angiotensin II receptor blockers
ASCVD risk score: 10-year atherosclerotic cardiovascular disease risk score
BHB: beta-hydroxybutyrate

366 BP: blood pressure
 367 CCI: continuous care intervention
 368 CCI-onsite: subset of CCI participants who selected to receive onsite education
 369 CCI-web: subset of CCI participants who selected to receive web-based education
 370 cIMT: carotid intima media thickness
 371 CVD: cardiovascular disease
 372 GDR: glucose disposal rate
 373 HOMA-IR: homeostatic model assessment of insulin resistance
 374 hsCRP: high sensitive C-reactive protein
 375 LP-IR: lipoprotein insulin resistance score
 376 T2D: type 2 diabetes
 377 UC: usual care
 378 VLDL-P: very low-density lipoprotein particle number
 379 WBC: white blood cell

380

381 Declarations

382

383 Ethics approval and consent to participate

384 This study was approved by the Franciscan Health Lafayette Institutional Review Board, and participants
 385 provided written informed consent.

386

387 Consent for publication

388 Not Applicable

389

390 Availability of data and material

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Competing interests

NHB, SJH, ALM, JPM, and SDP are employees of Virta Health Corp. and have been offered stock options. SDP and JSV are founders of Virta Health Corp. PTW and KDB are paid consultants of Virta Health Corp. WWC has no competing interests.

Funding

The study was funded by Virta Health Corp.

Authors' contributions

SJH, ALM, WWC, JPM, SDP and JSV conceptualized and designed the study. PTW performed the formal analysis. SJH and ALM contributed to the investigation. NHB and SJH wrote the original draft. NHB and PTW created the data tables and visualizations. All authors contributed to revising and editing of the manuscript. All authors read and approved the final manuscript.

Acknowledgements

The authors are extremely grateful to the research participants for offering their time and energy to participate in advancing scientific discovery. Thanks to Indiana University Health (IUH) staff, especially Tamara Hazbun, Monica Keyes, Danielle Wharff, Patti McKee, Joni Anderson, Zachary Roberts, Christina Selsor, and Douglas Jackson, and Virta Health staff Rachel Bolden, Sydney Rivera, and Deklin Veenhuizen for contributions to various aspects of the study including patient care, study coordination and data processing. Thanks to the health coaches who provided guidance to CCI participants: Brittanie Volk, Brent Creighton, Theresa Link, Bobbie Glon, and Marcy Abner. Thanks to Roxie McKee of IUH,

Dave Gibson and Jennifer Powers of Washington University, and Teryn Sapper and staff from the Volek Laboratory at The Ohio State University for assistance in sample analysis, storage and/or transportation logistics. Thanks to Angela Fountain, Irinia Shalaurova, and Jim Otvos of LabCorp for guidance on interpreting LipoProfile results. Thank you to Ronald Krauss for guidance on lipid analysis and Ethan Weiss for critical reading of the manuscript.

References

1. Benjamin EJ, Blaha MJ, Chiuve SE, Cushman M, Das SR, Deo R, et al. Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association. Circulation. American Heart Association, Inc; 2017;135:e146–e603.
2. Gregg EW, Gu Q, Cheng YJ, Narayan KMV, Cowie CC. Mortality trends in men and women with diabetes, 1971 to 2000. Ann Intern Med. 2007;147:149–55.
3. Centers for Disease Control and Prevention (CDC). National Diabetes Statistics Report, 2017. 2017 Jul pp. 1–20.
4. Martín-Timón I, Sevillano-Collantes C, Segura-Galindo A, Del Cañizo-Gómez FJ. Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength? World J Diabetes. 2014;5:444–70.
5. Saslow LR. An Online Intervention Comparing a Very Low-Carbohydrate Ketogenic Diet and Lifestyle Recommendations Versus a Plate Method Diet in Overweight Individuals With Type 2 Diabetes: A Randomized Controlled Trial. J Med Internet Res. 2017;19:e36.
6. Boden G, Sargrad K, Homko C, Mozzoli M, Stein TP. Effect of a low-carbohydrate diet on appetite, blood glucose levels, and insulin resistance in obese patients with type 2 diabetes. Ann Intern Med. 2005;142:403–11.

7. Yancy WS, Foy M, Chalecki AM, Vernon MC, Westman EC. A low-carbohydrate, ketogenic diet to treat type 2 diabetes. *Nutr Metab.* 2005;2:34.
8. Westman EC, Yancy WS, Mavropoulos JC, Marquart M, McDuffie JR. The effect of a low-carbohydrate, ketogenic diet versus a low-glycemic index diet on glycemic control in type 2 diabetes mellitus. *Nutr Metab.* 2008;5:36.
9. McKenzie A, Hallberg S, Creighton BC, Volk BM, Link T, Abner M, et al. A Novel Intervention Including Individualized Nutritional Recommendations Reduces Hemoglobin A1c Level, Medication Use, and Weight in Type 2 Diabetes. *JMIR Diabetes.* 2017;2:e5.
10. Hallberg SJ, McKenzie AL, Williams PT, Bhanpuri NH, Peters AL, Campbell WW, et al. Effectiveness and Safety of a Novel Care Model for the Management of Type 2 Diabetes at 1 Year: An Open-Label, Non-Randomized, Controlled Study. *Diabetes Therapy.* 2018;1–30.
11. Wood TR, Hansen R, Sigurðsson AF, Jóhannsson GF. The cardiovascular risk reduction benefits of a low-carbohydrate diet outweigh the potential increase in LDL-cholesterol. *Br J Nutr.* 2016;115:1126–8.
12. Mansoor N, Vinknes KJ, Veierød MB, Retterstøl K. Effects of low-carbohydrate diets v. low-fat diets on body weight and cardiovascular risk factors: a meta-analysis of randomised controlled trials. *Br J Nutr.* 2016;115:466–79.
13. Fruchart J-C, Sacks F, Hermans MP, Assmann G, Brown WV, Ceska R, et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. *The American Journal of Cardiology.* 2008;102:1K–34K.
14. Arca M, Pigna G, Favoccia C. Mechanisms of diabetic dyslipidemia: relevance for atherogenesis. *Curr Vasc Pharmacol.* 2012;10:684–6.
15. Volek JS, Fernandez ML, Feinman RD, Phinney SD. Dietary carbohydrate restriction induces a

- unique metabolic state positively affecting atherogenic dyslipidemia, fatty acid partitioning, and metabolic syndrome. *Prog. Lipid Res.* 2008;47:307–18.
16. Taskinen M-R, Borén J. New insights into the pathophysiology of dyslipidemia in type 2 diabetes. *Atherosclerosis.* 2015;239:483–95.
17. Ginsberg BH. Factors Affecting Blood Glucose Monitoring: Sources of Errors in Measurement. *Journal of Diabetes Science and Technology.* 2009;3:903–13.
18. Adiels M, Olofsson S-O, Taskinen M-R, Borén J. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. *Arteriosclerosis, Thrombosis, and Vascular Biology.* 2008;28:1225–36.
19. Cromwell WC, Otvos JD. Heterogeneity of low-density lipoprotein particle number in patients with type 2 diabetes mellitus and low-density lipoprotein cholesterol <100 mg/dl. *The American Journal of Cardiology.* 2006;98:1599–602.
20. Sniderman AD, St-Pierre AC, Cantin B, Dagenais GR, Després J-P, Lamarche B. Concordance/discordance between plasma apolipoprotein B levels and the cholesterol indexes of atherosclerotic risk. *The American Journal of Cardiology.* 2003;91:1173–7.
21. Otvos JD, Mora S, Shalaurova I, Greenland P, Mackey RH, Goff DC. Clinical implications of discordance between low-density lipoprotein cholesterol and particle number. *Journal of Clinical Lipidology.* 2011;5:105–13.
22. Cromwell WC, Otvos JD, Keyes MJ, Pencina MJ, Sullivan L, Vasan RS, et al. LDL Particle Number and Risk of Future Cardiovascular Disease in the Framingham Offspring Study - Implications for LDL Management. *Journal of Clinical Lipidology.* 2007;1:583–92.
23. Sniderman AD, Toth PP, Thanassoulis G, Furberg CD. An evidence-based analysis of the National

483 Lipid Association recommendations concerning non-HDL-C and apoB. *Journal of Clinical Lipidology*.
484 2016;10:1248–58.

485 24. Toth PP, Grabner M, Punekar RS, Quimbo RA, Cziraky MJ, Jacobson TA. Cardiovascular risk in
486 patients achieving low-density lipoprotein cholesterol and particle targets. *Atherosclerosis*.
487 2014;235:585–91.

488 25. Barter PJ, Ballantyne CM, Carmena R, Castro Cabezas M, Chapman MJ, Couture P, et al. Apo B
489 versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-
490 country panel. *J. Intern. Med.* Blackwell Publishing Ltd; 2006. pp. 247–58.

491 26. Seshadri P, Iqbal N, Stern L, Williams M, Chicano KL, Daily DA, et al. A randomized study
492 comparing the effects of a low-carbohydrate diet and a conventional diet on lipoprotein subfractions and
493 C-reactive protein levels in patients with severe obesity. *Am. J. Med.* 2004;117:398–405.

494 27. Volek JS, Sharman MJ, Gómez AL, DiPasquale C, Roti M, Pumerantz A, et al. Comparison of a very
495 low-carbohydrate and low-fat diet on fasting lipids, LDL subclasses, insulin resistance, and postprandial
496 lipemic responses in overweight women. *J Am Coll Nutr.* 2004;23:177–84.

497 28. Volek JS, Phinney SD, Forsythe CE, Quann EE, Wood RJ, Puglisi MJ, et al. Carbohydrate Restriction
498 has a More Favorable Impact on the Metabolic Syndrome than a Low Fat Diet. *Lipids.* 2008;44:297–309.

499 29. Kannel WB, Anderson K, Wilson PW. White blood cell count and cardiovascular disease. Insights
500 from the Framingham Study. *JAMA.* 1992;267:1253–6.

501 30. Yarnell JW, Baker IA, Sweetnam PM, Bainton D, O'Brien JR, Whitehead PJ, et al. Fibrinogen,
502 viscosity, and white blood cell count are major risk factors for ischemic heart disease. The Caerphilly and
503 Speedwell collaborative heart disease studies. *Circulation.* 1991;83:836–44.

504 31. Folsom AR, Aleksic N, Catellier D, Juneja HS, Wu KK. C-reactive protein and incident coronary

505 heart disease in the Atherosclerosis Risk In Communities (ARIC) study. *American Heart Journal*.
506 2002;144:233–8.

507 32. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and
508 the risk of future cardiovascular events among apparently healthy women. *Circulation*. 1998;98:731–3.

509 33. Libby P, Ridker PM, Hansson GK, Leducq Transatlantic Network on Atherothrombosis.
510 Inflammation in atherosclerosis: from pathophysiology to practice. *Journal of the American College of*
511 *Cardiology*. 2009;54:2129–38.

512 34. Biondi-Zoccai GGL, Abbate A, Liuzzo G, Biasucci LM. Atherothrombosis, inflammation, and
513 diabetes. *Journal of the American College of Cardiology*. 2003;41:1071–7.

514 35. Wong ND, Zhao Y, Quek RGW, Blumenthal RS, Budoff MJ, Cushman M, et al. Residual
515 atherosclerotic cardiovascular disease risk in statin-treated adults: The Multi-Ethnic Study of
516 Atherosclerosis. *Journal of Clinical Lipidology*. 2017;11:1223–33.

517 36. Sampson UK, Fazio S, Linton MF. Residual cardiovascular risk despite optimal LDL cholesterol
518 reduction with statins: the evidence, etiology, and therapeutic challenges. *Curr Atheroscler Rep*.
519 2012;14:1–10.

520 37. Group UPDS. Tight blood pressure control and risk of macrovascular and microvascular
521 complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. *BMJ*.
522 1998;317:703–13.

523 38. Schmieder RE, Ruilope L-M, Barnett AH. Renal protection with angiotensin receptor blockers: where
524 do we stand. *J. Nephrol*. 2011;24:569–80.

525 39. Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi G, et al. Angiotensin-converting enzyme
526 inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. *Ann Intern*

527 Med. 2001;135:73–87.

528 40. ADA. Standards of Medical Care in Diabetes - 2017. Diabetes Care; 2017;40.

529 41. Tremblay AJ, Morrisette H, Gagné J-M, Bergeron J, Gagné C, Couture P. Validation of the
530 Friedewald formula for the determination of low-density lipoprotein cholesterol compared with beta-
531 quantification in a large population. Clin. Biochem. 2004;37:785–90.

532 42. Jeyarajah EJ, Cromwell WC, Otvos JD. Lipoprotein particle analysis by nuclear magnetic resonance
533 spectroscopy. Clin. Lab. Med. 2006;26:847–70.

534 43. van Schalkwijk DB, de Graaf AA, Tsvitsivadze E, Parnell LD, van der Werff-van der Vat BJC, van
535 Ommen B, et al. Lipoprotein metabolism indicators improve cardiovascular risk prediction. Schäfer A,
536 editor. PLoS ONE. 2014;9:e92840.

537 44. May HT, Anderson JL, Winegar DA, Rollo J, Connelly MA, Otvos JD, et al. Utility of high density
538 lipoprotein particle concentration in predicting future major adverse cardiovascular events among patients
539 undergoing angiography. Clin. Biochem. 2016;49:1122–6.

540 45. Shalaurova I, Connelly MA, Garvey WT, Otvos JD. Lipoprotein Insulin Resistance Index: A
541 Lipoprotein Particle–Derived Measure of Insulin Resistance. Metabolic Syndrome and Related Disorders.
542 2014;12:422–9.

543 46. Goff DC, Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB, Gibbons R, et al. 2013 ACC/AHA
544 guideline on the assessment of cardiovascular risk: a report of the American College of
545 Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014. pp. S49–
546 73.

547 47. Doneen AL, Bale BF. Carotid intima-media thickness testing as an asymptomatic cardiovascular
548 disease identifier and method for making therapeutic decisions. Postgrad Med. 2013;125:108–23.

48. Stein JH, Korcarz CE, Hurst RT, Lonn E, Kendall CB, Mohler ER, et al. Use of Carotid Ultrasound to Identify Subclinical Vascular Disease and Evaluate Cardiovascular Disease Risk: A Consensus Statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force Endorsed by the Society for Vascular Medicine. *Journal of the American Society of Echocardiography*. 2008;21:93–111.
49. UK Prospective Diabetes Study UKPDS Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). *The Lancet*. 1998;352:837–53.
50. Volek JS, Sharman MJ, Forsythe CE. Modification of lipoproteins by very low-carbohydrate diets. *J. Nutr.* 2005;135:1339–42.
51. Nordmann AJ, Nordmann A, Briel M, Keller U, Yancy WS, Brehm BJ, et al. Effects of Low-Carbohydrate vs Low-Fat Diets on Weight Loss and Cardiovascular Risk Factors: A Meta-analysis of Randomized Controlled Trials. *Arch. Intern. Med.* 2006;166:285–93.
52. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. *BMJ*. 2003;326:1423–0.
53. Giugliano RP, Pedersen TR, Park J-G, De Ferrari GM, Gaciong ZA, Ceska R, et al. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. *Lancet*. 2017;390:1962–71.
54. Zuliani G, Volpato S, Dugo M, Vigna GB, Morieri ML, Maggio M, et al. Combining LDL-C and HDL-C to predict survival in late life: The InChianti study. Abete P, editor. *PLoS ONE*. 2017;12:e0185307.
55. Orozco-Beltran D, Gil-Guillen VF, Redon J, Martin-Moreno JM, Pallares-Carratala V, Navarro-Perez

571 J, et al. Lipid profile, cardiovascular disease and mortality in a Mediterranean high-risk population: The
572 ESCARVAL-RISK study. Vinciguerra M, editor. PLoS ONE. 2017;12:e0186196.

573 56. Ravnskov U, Diamond DM, Hama R, Hamazaki T, Hammarskjöld B, Hynes N, et al. Lack of an
574 association or an inverse association between low-density-lipoprotein cholesterol and mortality in the
575 elderly: a systematic review. BMJ Open. 2016;6:e010401.

576 57. Schmidt C, Bergstrom G. Apolipoprotein B and Apolipoprotein A-I in Vascular Risk Prediction-A
577 Review. Curr Pharm Des. 2014;20:6289–98.

578 58. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM. Low-density
579 lipoprotein subclass patterns and risk of myocardial infarction. JAMA. 1988;260:1917–21.

580 59. Tani S, Yagi T, Atsumi W, Kawauchi K, Matsuo R, Hirayama A. Relation between low-density
581 lipoprotein cholesterol/apolipoprotein B ratio and triglyceride-rich lipoproteins in patients with coronary
582 artery disease and type 2 diabetes mellitus: a cross-sectional study. Cardiovasc Diabetol. 2017;16:123.

583 60. Bertsch RA, Merchant MA. Study of the Use of Lipid Panels as a Marker of Insulin Resistance to
584 Determine Cardiovascular Risk. Perm J. 2015;19:4–10.

585 61. Ridker PM, Danielson E, Fonseca FAH, Genest J, Gotto AM Jr, Kastelein JJP, et al. Rosuvastatin to
586 Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. N Engl J Med.
587 2008;359:2195–207.

588 62. Albert MA, Danielson E, Rifai N, Ridker PM, PRINCE Investigators. Effect of statin therapy on C-
589 reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and
590 cohort study. JAMA. 2001;286:64–70.

591 63. Asher J, Houston M. Statins and C-reactive protein levels. J Clin Hypertens (Greenwich).
592 2007;9:622–8.

64. Youm Y-H, Nguyen KY, Grant RW, Goldberg EL, Bodogai M, Kim D, et al. The ketone metabolite β -hydroxybutyrate blocks NLRP3 inflammasome-mediated inflammatory disease. *Nat. Med.* 2015;21:263–9.
65. Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Journal of the American College of Cardiology.* 2017.
66. Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. *Lancet.* 2016;387:957–67.
67. Kuznik A, Mardekian J. Trends in utilization of lipid- and blood pressure-lowering agents and goal attainment among the U.S. diabetic population, 1999-2008. *Cardiovasc Diabetol.* 2011;10:31.
68. Shai I, Spence JD, Schwarzfuchs D, Henkin Y, Parraga G, Rudich A, et al. Dietary intervention to reverse carotid atherosclerosis. *Circulation.* 2010;121:1200–8.
69. Gress TW, Nieto FJ, Shahar E, Wofford MR, Brancati FL. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. *Atherosclerosis Risk in Communities Study. N. Engl. J. Med.* 2000;342:905–12.
70. Lorenz MW, Price JF, Robertson C, Bots ML, Polak JF, Poppert H, et al. Carotid intima-media thickness progression and risk of vascular events in people with diabetes: results from the PROG-IMT collaboration. *Diabetes Care.* 2015;38:1921–9.
71. Riley WA. Cardiovascular risk assessment in individual patients from carotid intimal-medial

thickness measurements. Curr Atheroscler Rep. 2004;6:225–31.

Figure Legends

Figure 1. Change in biomarkers for CCI group.

Bars indicate CCI group mean percent change in biomarkers based on the intention-to-treat analysis with missing values imputed. Percent change is computed as the change in mean values from baseline to one year divided by the mean baseline value. *Percent change* = $100 * [(1 \text{ year value} - \text{baseline value}) / (\text{baseline})]$. Negative values indicate a decrease from baseline to one year while positive values indicate an increase. The ** symbol after the biomarker label indicates a statistically significant within group change from baseline ($P < 0.0019$, P adjusted for multiple comparisons). Error bars represent \pm SE. *SE as Percent* = $100 * [(1 \text{ year value SE}) / (\text{baseline})]$

Figure 2. Change in biomarkers for UC group.

Bars indicate UC group mean percent change in biomarkers based on the intention-to-treat analysis with missing values imputed. Percent change is computed as the change in mean values from baseline to one year divided by the mean baseline value. *Percent change* = $100 * [(1 \text{ year value} - \text{baseline value}) / (\text{baseline})]$. Negative values indicate a decrease from baseline to one year while positive values indicate an increase. (None of the within group changes were statistically significant, i.e. all $P > 0.0019$, P adjusted for multiple comparisons.) Error bars represent \pm SE. *SE as Percent* = $100 * [(1 \text{ year value SE}) / (\text{baseline})]$

Supplementary Figure 1. Distribution of changes in selected biomarkers for CCI and UC completers

639 Histograms of changes at one year for CCI (blue) and UC (gray) are overlaid. Very few ($\leq 1\%$) CCI
 640 participants demonstrated changes in an undesirable direction at one year that was outside the range of
 641 changes observed in the UC group for key lipid and lipoprotein particles. (A) Apolipoprotein B (B)
 642 Apolipoprotein A1 (C) Apolipoprotein B/Apolipoprotein A1 ratio (D) LDL-P (E) Small LDL-P (F) Large
 643 VLDL-P (G) Triglyceride/HDL-C ratio
 644

Table 1. Baseline characteristics Continuous Care Intervention (CCI) and Usual Care (UC) groups.

	All		Completers with data	
	N	Mean (SD) or ±SE	N	Mean (SD) or ±SE
Age (years)				
CCI-all education ¹	262	54 (8)	218	54 (8)
Usual care ¹	87	52 (10)	78	52 (10)
CCI-all vs. usual care ²		1 ± 1		2 ± 1*
Female (%)				
CCI-all education ¹	262	66.8 ± 2.9	218	65.1 ± 3.2
Usual care ¹	87	58.6 ± 5.3	78	60.3 ± 5.5
CCI-all vs. usual care ²		8.2 ± 6.0		4.9 ± 6.4
Smokers (%)				
CCI-all education ¹	211	3.8 ± 1.3	176	4.0 ± 1.5
Usual care ¹	87	14.9 ± 3.8	78	14.1 ± 3.9
CCI-all vs. usual care ²		-11.2 ± 4.0†		-10.1 ± 4.2*
Weight-clinic (kg)				
CCI-all education ¹	257	116.5 (25.9)	184	115.4 (24.6)
Usual care ¹	83	105.6 (22.2)	69	106.8 (22.2)
CCI-all vs. usual care ²		10.9 ± 2.9‡		8.6 ± 3.2†
BMI (kg·m⁻²)				
CCI-all education ¹	257	40.4 (8.8)	184	39.9 (7.9)
Usual care ¹	83	36.7 (7.3)	69	37.1 (7.6)
CCI-all vs. usual care ²		3.7 ± 1.0‡		2.7 ± 1.1†
Hemoglobin A1c (%)				
CCI-all education ¹	262	7.60 (1.50)	204	7.49 (1.40)
Usual care ¹	87	7.64 (1.76)	72	7.74 (1.82)
CCI-all vs. usual care ²		-0.04 ± 0.21		-0.25 ± 0.24

Systolic blood pressure (mmHg)				
CCI-all education ¹	260	132 (14)	187	133 (15)
Usual care ¹	79	130 (14)	67	129 (13)
CCI-all vs. usual care ²		2 ± 2		4 ± 2*
Diastolic blood pressure (mmHg)				
CCI-all education ¹	260	82 (8)	187	82 (8)
Usual care ¹	79	82 (9)	67	81 (8)
CCI-all vs. usual care ²		0 ± 1		0 ± 1
ApoB (mg·dL⁻¹)				
CCI-all education ¹	248	105 (29)	186	103 (28)
Usual care ¹	79	107 (28)	59	106 (30)
CCI-all vs. usual care ²		-2 ± 4		-2
ApoA1 (mg·dL⁻¹)				
CCI-all education ¹	248	146 (28)	185	146 (29)
Usual care ¹	79	149 (22)	59	148 (21)
CCI-all vs. usual care ²		-3 ± 3		-2 ± 3
ApoB/ApoA1 ratio				
CCI-all education ¹	248	0.74 (0.23)	185	0.73 (0.23)
Usual care ¹	79	0.73 (0.23)	59	0.73 (0.25)
CCI-all vs. usual care ²		0.01 ± 0.03		0.00 ± 0.04
Triglycerides (mg·dL⁻¹)				
CCI-all education ¹	247	197 (143)	186	201 (153)
Usual care ¹	79	283 (401)	59	297 (458)
CCI-all vs. usual care ²		-86 ± 46*		-97 ± 61
LDL-C (mg·dL⁻¹)				
CCI-all education ¹	232	103 (33)	172	100 (33)
Usual care ¹	70	102 (36)	48	100 (38)

CCI-all vs. usual care ²		1 ± 5		0 ± 6
HDL-C (mg·dL⁻¹)				
CCI-all education ¹	247	42 (13)	186	42 (14)
Usual care ¹	79	38 (11)	59	37 (11)
CCI-all vs. usual care ²		$5 \pm 2^\dagger$		$5 \pm 2^\dagger$
Triglycerides/HDL-C ratio				
CCI-all education ¹	247	5.9 (7.1)	186	6.1 (7.9)
Usual care ¹	79	10.5 (23.2)	59	11.5 (26.5)
CCI-all vs. usual care ²		-4.6 ± 2.6		-5.4 ± 3.5
Large VLDL-P (nmol·L⁻¹)				
CCI-all education ¹	259	10 (8)	203	9 (8)
Usual care ¹	83	12 (12)	68	12 (13)
CCI-all vs. usual care ²		-2 ± 1		-2 ± 2
Total LDL-P (nmol·L⁻¹)				
CCI-all education ¹	259	1300 (465)	203	1296 (476)
Usual care ¹	83	1289 (511)	68	1243 (484)
CCI-all vs. usual care ²		11 ± 63		52 ± 68
Small LDL-P (nmol·L⁻¹)				
CCI-all education ¹	259	774 (377)	203	778 (378)
Usual care ¹	83	719 (322)	68	699 (326)
CCI-all vs. usual care ²		55 ± 42		789 ± 48
LDL-particle size (nm)				
CCI-all education ¹	259	20.30 (0.55)	201	20.3 (0.55)
Usual care ¹	83	20.33 (0.56)	68	20.32 (0.55)
CCI-all vs. usual care ²		-0.03 ± 0.07		-0.03 ± 0.08
Total HDL-P (μmol·L⁻¹)				
CCI-all education ¹	259	31.3 (6.4)	203	31.7 (6.4)
Usual care ¹	83	29.9 (5.8)	68	30.2 (6.0)

CCI-all vs. usual care ²		1.4 ± 0.8		1.5 ± 0.9
Large HDL-P (μmol·L⁻¹)				
CCI-all education ¹	259	4.3 (2.5)	203	4.2 (2.5)
Usual care ¹	83	3.8 (2.1)	68	3.8 (2.1)
CCI-all vs. usual care ²		0.4 ± 0.3		0.4 ± 0.3
LP-IR score				
CCI-all education ¹	259	72 (17)	203	72 (18)
Usual care ¹	83	75 (16)	68	74 (17)
CCI-all vs. usual care ²		-3 ± 2		-2 ± 2
C-reactive protein (mg·L⁻¹)				
CCI-all education ¹	249	8.5 (14.5)	193	9.0 (16.1)
Usual care ¹	85	8.9 (8.6)	70	9.1 (9.0)
CCI-all vs. usual care ²		-0.3 ± 1.3		-0.1 ± 1.6
WBC				
CCI-all education ¹	260	7.2 (1.9)	204	7.1 (1.8)
Usual care ¹	86	8.1 (2.4)	72	8.3 (2.4)
CCI-all vs. usual care ²		-0.9 ± 0.3†		-1.2 ± 0.3§
10-year ASCVD risk (%)				
CCI-all education ¹	198	11.1 (9.1)	135	12.1 (9.3)
Usual care ¹	72	11.8 (10.8)	55	11.4 (10.8)
CCI-all vs. usual care ²		-0.6 ± 1.4		0.8 ± 1.6
CIMT-average (mm)				
CCI-all education ¹	236	0.681 (0.108)	144	0.692 (0.113)
Usual care ¹	84	0.681 (0.116)	68	0.680 (0.111)
CCI-all vs. usual care ²		-0.001 ± 0.014		0.013 ± 0.016
Statin (%)				
CCI-all education ¹	262	50.0 ± 3.1	218	51.8 ± 3.4
Usual care ¹	87	58.6 ± 5.3	73	54.8 ± 5.8

CCI-all vs. usual care ²		-8.6 ± 6.1		-3.0 ± 6.7
Any antihypertensive medication (%)				
CCI-all education ¹	262	67.2 ± 2.9	218	68.4 ± 3.2
Usual care ¹	87	52.9 ± 5.4	73	50.7 ± 5.9
CCI-all vs. usual care ²		14.3 ± 6.1*		17.7 ± 6.7†
ACE or ARB (%)				
CCI-all education ¹	262	29.4 ± 2.8	218	28.0 ± 3.0
Usual care ¹	87	18.4 ± 4.2	73	16.4 ± 4.3
CCI-all vs. usual care ²		11.0 ± 5.0*		11.5 ± 5.3*
Diuretics (%)				
CCI-all education ¹	262	40.8 ± 3.0	218	41.3 ± 3.3
Usual care ¹	87	29.9 ± 4.9	73	24.7 ± 5.0
CCI-all vs. usual care ²		11.0 ± 5.8		16.6 ± 6.1†
¹ Mean and standard deviations for continuous variables, percents and standard errors for categorical variables ² Difference between means or percentages ± 1 standard error of the difference. Significant baseline difference between means or percentages at 0.05 ≤ P < 0.01 (*); 0.01 ≤ P < 0.001 (†); 0.001 ≤ P < 0.0001 (§); and P < 0.0001 (§§).				

645

Table 2. One-year Biomarker Change Continuous Care Intervention compared to Usual Care groups.									
	Completers						All starters (Dropouts imputed) ⁴		
	N		Unadjusted		Adjusted for baseline ³		Unadjusted		
		One Year Mean \pm SE	Difference (SD) or \pm SE	Signif- icance ⁵	Difference \pm SE	Signif- icance ⁵	One Year Mean \pm SE	Difference \pm SE	Signif- icance ⁵
ΔWeight-clinic (kg)									
CCI-all education ¹	184	101.2 \pm 1.6	-14.2 (10.3)	<10 ⁻¹⁶	-13.8 \pm 0.6	<10 ⁻¹⁶	102.7 \pm 1.5	-13.8 \pm 0.7	<10 ⁻¹⁶
Usual care ¹	69	106.8 \pm 2.7	0.04 (5.9)	0.95	-1.1 \pm 1.1	0.29	107.3 \pm 2.6	-0.2 \pm 0.8	0.85
CCI-all vs. usual care ²			-14.3 \pm 1.0	<10 ⁻¹⁶	-12.7 \pm 1.3	<10 ⁻¹⁶		-13.7 \pm 1.1	<10 ⁻¹⁶
ΔHemoglobin A1c (%)									
CCI-all education ¹	204	6.20 \pm 0.07	-1.29 (1.32)	<10 ⁻¹⁶	-1.32 \pm 0.09	<10 ⁻¹⁶	6.29 \pm 0.07	-1.30 \pm 0.09	<10 ⁻¹⁶
Usual care ¹	72	7.94 \pm 0.22	0.20 (1.35)	0.21	0.22 \pm 0.16	0.17	7.84 \pm 0.19	0.20 \pm 0.15	0.18
CCI-all vs. usual care ²			-1.49 \pm 0.18	4.4x10 ⁻¹⁶	-1.54 \pm 0.19	4.4x10 ⁻¹⁶		-1.50 \pm 0.17	<10 ⁻¹⁶
ΔSystolic blood pressure (mmHg)									
CCI-all education ¹	187	126 \pm 1	-7 (16)	1.3x10 ⁻⁸	-7 \pm 1	1.6x10 ⁻⁷	126 \pm 1	-6 \pm 1	1.3x10 ⁻⁸
Usual care ¹	67	129 \pm 2	0 (18)	0.91	0 \pm 2	0.83	129 \pm 2	-1 \pm 2	0.67
CCI-all vs. usual care ²			-7 \pm 2	0.005	-6 \pm 3	0.02		-5 \pm 2	0.02
ΔDiastolic blood pressure (mmHg)									

CCI-all education ¹	187	78 ± 1	-4 (9)	1.4x10 ⁻⁷	-4 ± 1	6.2x10 ⁻⁷	79 ± 1	-4 ± 1	7.2x10 ⁻⁸
Usual care ¹	67	81 ± 1	0 (10)	0.92	0 ± 1	0.75	81 ± 1	-1 ± 1	0.45
CCI-all vs. usual care ²			-3 ± 1	0.01	-3 ± 1	0.03		-3 ± 1	0.06
ΔApoB (mg·dL⁻¹)									
CCI-all education ¹	186	103 ± 2	-1 (24)	0.69	-0 ± 2	0.82	104 ± 2	-2 ± 2	0.37
Usual care ¹	59	107 ± 5	2 (37)	0.75	1 ± 4	0.9	106 ± 4	0 ± 4	0.95
CCI-all vs. usual care ²			-2 ± 5	0.66	-1 ± 5	0.83		-2 ± 5	0.67
ΔApoA1 (mg·dL⁻¹)									
CCI-all education ¹	185	160 ± 3	14 (24)	8.9x10 ⁻¹⁶	14 ± 2	4.4x10 ⁻¹⁶	160 ± 2	14 ± 2	<10 ⁻¹⁶
Usual care ¹	59	145 ± 3	-3 (19)	0.18	-2 ± 3	0.55	147 ± 3	-2 ± 3	0.37
CCI-all vs. usual care ²			18 ± 3	4.7x10 ⁻⁹	16 ± 4	2.2x10 ⁻⁵		17 ± 3	1.4x10 ⁻⁷
ΔApoB/ApoA1									
CCI-all education ¹	185	0.67 ± 0.02	-0.06 (0.17)	1.8x10 ⁻⁶	-0.06 ± 0.02	0.003	0.67 ± 0.02	-0.07 ± 0.01	1.9x10 ⁻⁷
Usual care ¹	59	0.76 ± 0.04	0.03 (0.29)	0.42	0.02 ± 0.03	0.5	0.74 ± 0.03	0.02 ± 0.03	0.58
CCI-all vs. usual care ²			-0.09 ± 0.04	0.02	-0.08 ± 0.03	0.02		-0.09 ± 0.03	0.01
ΔTriglycerides (mg·dL⁻¹)									
CCI-all education ¹	186	151 ± 11	-49 (168)	5.6x10 ⁻⁵	-50 ± 16	0.001	148 ± 12	-48 ± 13	<10 ⁻¹⁶
Usual care ¹	59	327 ± 65	30 (301)	0.44	31 ± 29	0.27	305 ± 48	28 ± 32	0.43
CCI-all vs. usual care ²			-80 ± 41	0.05	-81 ± 33	0.02		-76 ± 35	9.9x10 ⁻⁷
ΔLDL-C (mg·dL⁻¹)									

CCI-all education ¹	172	111 ± 3	11 (32)	7.7x10 ⁻⁶	11 ± 3	2.6x10 ⁻⁵	113 ± 3	10 ± 2	4.9x10 ⁻⁵
Usual care ¹	48	90 ± 4	-11 (38)	0.05	-11 ± 5	0.03	90 ± 5	-11 ± 5	0.02
CCI-all vs. usual care ²			22 ± 6	0.0003	22 ± 6	0.0002		21 ± 5	9.9x10 ⁻⁵
ΔHDL-C (mg·dL⁻¹)									
CCI-all education ¹	186	50 ± 1	8 (12)	<10 ⁻¹⁶	7 ± 1	<10 ⁻¹⁶	50 ± 1	8 ± 1	<10 ⁻¹⁶
Usual care ¹	59	35 ± 2	-2 (9)	0.15	-1 ± 2	0.69	37 ± 2	-1 ± 1	0.41
CCI-all vs. usual care ²			9 ± 1	1.7x10 ⁻¹⁰	8 ± 2	9.9x10 ⁻⁶		9 ± 2	1.2x10 ⁻⁸
ΔTriglycerides/HDL-C ratio									
CCI-all education ¹	186	4.3 ± 0.6	-1.8 (9.4)	<10 ⁻¹⁶	-1.9 ± 0.9	<10 ⁻¹⁶	4.1 ± 0.6	-1.6 ± 0.7	<10 ⁻¹⁶
Usual care ¹	59	12.5 ± 2.7	0.9 (16.1)	0.1	1.2 ± 1.6	0.16	11.2 ± 2.1	1.0 ± 1.7	0.24
CCI-all vs. usual care ²			-2.8 ± 2.2	3.1x10 ⁻¹⁰	-3.1 ± 1.8	5.5x10 ⁻⁷		-2.6 ± 1.8	4.5x10 ⁻⁹
ΔLarge VLDL-P (nmol·L⁻¹)									
CCI-all education ¹	203	6 ± 1	-4 (7)	5.6x10 ⁻¹⁵	-4 ± 1	1.6x10 ⁻¹⁴	6 ± 1	-4 ± 1	4.2x10 ⁻¹⁵
Usual care ¹	68	12 ± 2	0 (8)	0.71	0 ± 1	0.60	12 ± 1	0 ± 1	0.77
CCI-all vs. usual care ²			-3 ± 1	0.001	-3 ± 1	0.002		3 ± 1	0.0007
ΔTotal LDL-P (nmol·L⁻¹)									
CCI-all education ¹	203	1234 ± 30	-62 (375)	0.02	-57 ± 29	0.05	1235 ± 29	-64 ± 26	0.02
Usual care ¹	68	1196 ± 60	-47 (491)	0.43	-67 ± 53	0.21	1231 ± 57	-57 ± 56	0.31
CCI-all vs. usual care ²			-15 ± 65	0.82	10 ± 62	0.87		-7 ± 62	0.91
ΔSmall LDL-P (nmol·L⁻¹)									


CCI-all education ¹	203	614 ± 22	-164 (332)	2.2x10 ⁻¹²	-161 ± 24	4.1x10 ⁻¹¹	613 ± 21	-161 ± 23	1.2x10 ⁻¹²
Usual care ¹	68	724 ± 44	25 (370)	0.57	16 ± 45	0.71	740 ± 41	18 ± 42	0.67
CCI-all vs. usual care ²			-189 ± 51	0.0002	-177 ± 52	0.0007		-179 ± 48	0.0002
ΔLDL-particle size (nm)									
CCI-all education ¹	201	20.53 ± 0.04	0.23 (0.54)	1.7x10 ⁻⁹	0.23 ± 0.04	8.9x10 ⁻⁹	20.53 ± 0.04	0.23 ± 0.04	6.0x10 ⁻¹⁰
Usual care ¹	68	20.25 ± 0.07	-0.08 (0.53)	0.24	-0.08 ± 0.07	0.25	20.25 ± 0.07	-0.07 ± 0.06	0.25
CCI-all vs. usual care ²			0.30 ± 0.07	4.4x10 ⁻⁵	0.31 ± 0.08	0.0002		0.30 ± 0.07	3.8x10 ⁻¹⁵
ΔTotal HDL-P (μmol·L⁻¹)									
CCI-all education ¹	203	33.2 ± 0.5	1.5 (4.9)	1.2x10 ⁻⁵	1.5 ± 0.4	2.1x10 ⁻⁵	32.8 ± 0.4	1.5 ± 0.3	5.6x10 ⁻⁶
Usual care ¹	68	29.4 ± 0.8	-0.8 (4.7)	0.15	-0.8 ± 0.6	0.23	29.2 ± 0.7	-0.7 ± 0.6	0.23
CCI-all vs. usual care ²			2.3 ± 0.7	0.0004	2.3 ± 0.7	0.003		2.2 ± 0.7	0.0008
ΔLarge HDL-P (μmol·L⁻¹)									
CCI-all education ¹	203	5.3 ± 0.2	1.0 (2.2)	2.5x10 ⁻¹¹	1.0 ± 0.2	4.1x10 ⁻¹¹	5.3 ± 0.2	1.0 ± 0.2	1.2x10 ⁻¹¹
Usual care ¹	68	3.9 ± 0.3	0.1 (1.6)	0.69	0.2 ± 0.3	0.44	3.9 ± 0.3	0.1 ± 0.2	0.74
CCI-all vs. usual care ²			0.9 ± 0.3	0.0002	0.8 ± 0.3	0.01		0.9 ± 0.3	0.0004
ΔLP-IR score									
CCI-all education ¹	203	58 ± 2	-14 (18)	<10 ⁻¹⁶	-14 ± 1	<10 ⁻¹⁶	58 ± 1	-14 ± 1	<10 ⁻¹⁶
Usual care ¹	68	74 ± 2	-1 (16)	0.73	-2 ± 2	0.41	75 ± 2	-1 ± 2	0.74
CCI-all vs. usual care ²			-13 ± 2	3.8x10 ⁻⁹	-12 ± 3	6.2x10 ⁻⁶		-13 ± 2	6.2x10 ⁻⁹
ΔC-reactive protein (mg·L⁻¹)									

CCI-all education ¹	193	5.7 ± 0.5	-3.3 (13.4)	<10 ⁻⁸	-3.1 ± 1.0	<10 ⁻¹⁶	5.6 ± 0.6	-3.6 ± 1.1	<10 ⁻¹⁶
Usual care ¹	70	10.4 ± 1.8	1.3 (13.3)	0.94	0.9 ± 1.7	0.88	10.3 ± 1.6	1.3 ± 1.5	0.93
CCI-all vs. usual care ²			-4.7 ± 1.9	1.2x10 ⁻⁶	-4.0 ± 2.0	3.0x10 ⁻⁵		-4.9 ± 1.8	9.3x10 ⁻⁷
ΔWBC (k•mm⁻³)									
CCI-all education ¹	204	6.5 ± 0.1	-0.7 (1.4)	2.1x10 ⁻¹¹	-0.7 ± 0.1	2.1x10 ⁻¹¹	6.6 ± 0.1	-0.7 ± 0.1	3.2x10 ⁻¹¹
Usual care ¹	72	8.3 ± 0.3	-0.1 (1.6)	0.76	-0.1 ± 0.2	0.74	8.1 ± 0.3	-0.1 ± 0.2	0.76
CCI-all vs. usual care ²			-0.6 ± 0.2	0.003	-0.6 ± 0.2	0.004		-0.6 ± 0.2	0.003
Δ10-year ASCVD risk (%)									
CCI-all education ¹	135	10.5 ± 0.7	1.6 (5.4)	0.0004	-1.5 ± 0.6	0.01	9.6 ± 0.5	-1.3 ± 0.3	4.9x10 ⁻⁵
Usual care ¹	55	12.7 ± 1.5	1.4 (9.3)	0.28	1.1 ± 1.0	0.27	12.9 ± 1.2	1.2 ± 0.9	0.17
CCI-all vs. usual care ²			03.0 ± 1.3	0.03	-2.6 ± 1.2	0.03		-2.6 ± 1.0	0.008
ΔCIMT-average (mm)									
CCI-all education ¹	144	0.695 ± 0.009	0.002 (0.055)	0.63	0.003 ± 0.004	0.45	0.685 ± 0.010	0.002 ± 0.004	0.65
Usual care ¹	68	0.680 ± 0.013	0.004 (0.041)	0.37	0.002 ± 0.006	0.74	0.680 ± 0.013	0.001 ± 0.006	0.87
CCI-all vs. usual care ²			-0.002 ± 0.007	0.74	0.001 ± 0.008	0.87		0.001 ± 0.007	0.88
ΔStatin (%)									
CCI-all education ¹	218	48.2 ± 3.4	-3.7 (34.4)	0.12	-3.6 ± 2.4	0.13	46.7 ± 3.2	-3.3 ± 2.3	0.15
Usual care ¹	73	64.4 ± 5.6	9.6 (37.9)	0.03	9.5 ± 4.3	0.03	67.4 ± 5.4	8.8 ± 4.3	0.04
CCI-all vs. usual care ²			-13.3 ± 5.0	0.008	-13.2 ± 5.0	0.009		-12.1 ± 4.9	0.01
ΔAny antihypertensive medication (%)									

CCI-all education ¹	218	56.4 ± 3.4	-11.9 (42.3)	3.2x10 ⁻⁵	-11.9 ± 2.9	3.6x10 ⁻⁵	55.8 ± 3.3	-11.4 ± 2.8	5.3x10 ⁻⁵
Usual care ¹	73	60.3 ± 5.8	9.6 (41.4)	0.05	9.6 ± 5.1	0.06	61.2 ± 5.6	8.3 ± 4.8	0.09
CCI-all vs. usual care ²			-21.5 ± 5.6	0.0002	-21.6 ± 6.0	0.0004		-19.7 ± 5.6	0.0004
ΔACE or ARB (%)									
CCI-all education ¹	218	28.9 ± 3.1	0.9 (27.1)	0.62	1.5 ± 1.9	0.42	30.0 ± 2.9	0.6 ± 1.9	0.76
Usual care ¹	73	21.9 ± 4.9	5.5 (28.3)	0.1	3.7 ± 3.3	0.27	23.4 ± 4.7	5.0 ± 3.3	0.13
CCI-all vs. usual care ²			-4.6 ± 3.8	0.23	-2.1 ± 3.9	0.59		-4.4 ± 3.8	0.24
ΔDiuretics (%)									
CCI-all education ¹	218	31.7 ± 3.2	-9.6 (41.3)	0.0006	-9.5 ± 2.7	0.0004	31.3 ± 3.1	-9.7 ± 2.7	0.0004
Usual care ¹	73	30.1 ± 5.4	5.5 (32.9)	0.16	5.2 ± 4.8	0.28	33.0 ± 5.3	3.2 ± 4.1	0.44
CCI-all vs. usual care ²			-15.1 ± 4.8	0.001	-14.7 ± 5.6	0.009		-12.8 ± 4.9	0.009
¹ Means (standard deviations) are presented. Sample sizes, means, and significance levels refer to subjects with baseline and one-year measurements for <i>completers</i> , and to 349 subjects (262 intervention and 87 usual care) for <i>all starters</i> . Significance levels for <i>completers</i> refer to one-sample t-test with or without adjustment. Untransformed triglyceride and C-reactive protein values are presented, however, their statistical significances were based on their log-transformed values. All CC refers to the CCI-web and CCI-on-site combined. ² Mean differences ± one standard error. Significance levels refer to two-sample t-test or analysis of covariance for the differences. ³ Adjusted for sex, age, baseline BMI, baseline insulin use (user vs. non-user), and African-American race. ⁴ Imputed values based on 700 iterations from multivariate normal regression. ⁵ A significance level of P<0.0019 ensures overall simultaneous significance of P≤0.05 over the 26 variables using Bonferroni correction.									

647
648

Intention-to-treat (Missing Values Imputed)



Intention-to-treat (Missing Values Imputed)

